I currently focus on opinions and evaluations of US patents, patent due diligence, prosecution and patenting strategies, including for multinational companies.I also work with contracts including licensing and complex multiparty agreements,I remain the sole authored book U.S. Patent Opinions and Evaluations, to be published in its third edition in autumn 2016 by LexisNexis, The third edition has been extensively revised for AIA issues, including post issuance proceedings.I am a frequent speaker and writer on developing matters in US IP law, including on AIA related issues and changes in US law in response to IP law of other countries.I remain a Special Lecturer on US Patent Law for the University of Houston - Global Unisource annual program in Houston for visiting Chinese IP professionals.Covered technologies range from all aspects of biotechnology, including pharmaceuticals cancer biology, biochemistry, medical devices, personalized medicine, including devices and methods integrating biotechnology and computer software, plant patents, and alternative energy.

I currently focus on opinions and evaluations of US patents, patent due diligence, prosecution and patenting strategies, including for multinational companies.I also work with contracts including licensing and complex multiparty agreements,I remain the sole authored book U.S. Patent Opinions and Evaluations, to be published in its third edition in autumn 2016 by LexisNexis, The third edition has been extensively revised for AIA issues, including post issuance proceedings.I am a frequent speaker and writer on developing matters in US IP law, including on AIA related issues and changes in US law in response to IP law of other countries.I remain a Special Lecturer on US Patent Law for the University of Houston - Global Unisource annual program in Houston for visiting Chinese IP professionals.Covered technologies range from all aspects of biotechnology, including pharmaceuticals cancer biology, biochemistry, medical devices, personalized medicine, including devices and methods integrating biotechnology and computer software, plant patents, and alternative energy.

International intellectual property law practice included, but was not limited to, biotechnology, client counseling on US and international patenting strategies; licensing and other agreements; and evaluations and opinions on US patents. Areas of practice concentrated on biotechnology, pharmaceuticals (including biologics and FDA-related issues), and alternative energy (including, but not limited to, biotechnological aspects of alternative energy). Practice also included representing technology companies in all IP related aspects, including large multinational companies and start-up companies in identifying, obtaining, enforcing and and protecting IP rights.

Intellectual property law, primarily, but not exclusively, focused on biotechnology; client counseling on US and international patenting strategies; licensing and other agreements. Significant practice in evaluations and opinions of US patents. Sole author of the treatise US Patent Opinions and Evaluations, first edition published by Oxford University Press. Frequent speaker and writer in national journals on contemporary IP issues.Participated as sole technological chair in defending a major multinational pharmaceutical company against an Ivy League University in a case involving recombinant DNA technology (potential damages ca. $900 million - settled significantly lower before appeal).See Trustees of Columbia University v. Roche Diagnostics GmbH, 126 F. Supp.2d. 16 (D. Mass. 2000) (Discussed, e.g., in 17 Harv. J. Law & Tec 583 (Spring, 2004))..

Associate in intellectual property law, included biotechnology, pharmaceutical, agricultural technologies, client counseling, and licensing.Worked out of both New Orleans and Houston offices while attending law school full time.

Technical Consultant in intellectual property law, including in biotechnology, pharmaceutical, agricultural technologies, client counseling, and licensing.